Remote Neurodegeneration: Multiple Actors for One Play
Remote neurodegeneration significantly influences the clinical outcome in many central nervous system (CNS) pathologies, such as stroke, multiple sclerosis, and traumatic brain and spinal cord injuries. Because these processes develop days or months after injury, they are accompanied by a therapeuti...
Gespeichert in:
Veröffentlicht in: | Molecular neurobiology 2014-10, Vol.50 (2), p.368-389 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 389 |
---|---|
container_issue | 2 |
container_start_page | 368 |
container_title | Molecular neurobiology |
container_volume | 50 |
creator | Viscomi, Maria Teresa Molinari, Marco |
description | Remote neurodegeneration significantly influences the clinical outcome in many central nervous system (CNS) pathologies, such as stroke, multiple sclerosis, and traumatic brain and spinal cord injuries. Because these processes develop days or months after injury, they are accompanied by a therapeutic window of opportunity. The complexity and clinical significance of remote damage is prompting many groups to examine the factors of remote degeneration. This research is providing insights into key unanswered questions, opening new avenues for innovative neuroprotective therapies. In this review, we evaluate data from various remote degeneration models to describe the complexity of the systems that are involved and the importance of their interactions in reducing damage and promoting recovery after brain lesions. Specifically, we recapitulate the current data on remote neuronal degeneration, focusing on molecular and cellular events, as studied in stroke and brain and spinal cord injury models. Remote damage is a multifactorial phenomenon in which many components become active in specific time frames. Days, weeks, or months after injury onset, the interplay between key effectors differentially affects neuronal survival and functional outcomes. In particular, we discuss apoptosis, inflammation, oxidative damage, and autophagy—all of which mediate remote degeneration at specific times. We also review current findings on the pharmacological manipulation of remote degeneration mechanisms in reducing damage and sustaining outcomes. These novel treatments differ from those that have been proposed to limit primary lesion site damage, representing new perspectives on neuroprotection. |
doi_str_mv | 10.1007/s12035-013-8629-x |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1611612936</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3448959071</sourcerecordid><originalsourceid>FETCH-LOGICAL-c475t-6b8fc1c74f04ab5b17d9d01f5641dbe6ba7d6c902f823812d19130b6d1fcd283</originalsourceid><addsrcrecordid>eNp1kN9LwzAQx4Mobk7_AF-k4Isv1VySpolvY_gLphPZe2ibZHS0zUxa2P57OzpFBOHgHu5z3zs-CF0CvgWM07sABNMkxkBjwYmMt0doDEkiYwBBjtEYC0njlDMxQmchrDEmBHB6ikaEMUaYgDHiH6Z2rYneTOedNivTGJ-1pWvuo9euastNZaJp0TofIut8tGhM9F5lu3N0YrMqmItDn6Dl48Ny9hzPF08vs-k8LliatDHPhS2gSJnFLMuTHFItNQabcAY6NzzPUs0LiYkVhAogGiRQnHMNttBE0Am6GWI33n12JrSqLkNhqiprjOuCAg59EUl5j17_Qdeu803_nIKE85RJSmVPwUAV3oXgjVUbX9aZ3ynAau9UDU5V71Ttnaptv3N1SO7y2uifjW-JPUAGIPSjZmX8r9P_pn4BYfuAWQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1566749339</pqid></control><display><type>article</type><title>Remote Neurodegeneration: Multiple Actors for One Play</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Viscomi, Maria Teresa ; Molinari, Marco</creator><creatorcontrib>Viscomi, Maria Teresa ; Molinari, Marco</creatorcontrib><description>Remote neurodegeneration significantly influences the clinical outcome in many central nervous system (CNS) pathologies, such as stroke, multiple sclerosis, and traumatic brain and spinal cord injuries. Because these processes develop days or months after injury, they are accompanied by a therapeutic window of opportunity. The complexity and clinical significance of remote damage is prompting many groups to examine the factors of remote degeneration. This research is providing insights into key unanswered questions, opening new avenues for innovative neuroprotective therapies. In this review, we evaluate data from various remote degeneration models to describe the complexity of the systems that are involved and the importance of their interactions in reducing damage and promoting recovery after brain lesions. Specifically, we recapitulate the current data on remote neuronal degeneration, focusing on molecular and cellular events, as studied in stroke and brain and spinal cord injury models. Remote damage is a multifactorial phenomenon in which many components become active in specific time frames. Days, weeks, or months after injury onset, the interplay between key effectors differentially affects neuronal survival and functional outcomes. In particular, we discuss apoptosis, inflammation, oxidative damage, and autophagy—all of which mediate remote degeneration at specific times. We also review current findings on the pharmacological manipulation of remote degeneration mechanisms in reducing damage and sustaining outcomes. These novel treatments differ from those that have been proposed to limit primary lesion site damage, representing new perspectives on neuroprotection.</description><identifier>ISSN: 0893-7648</identifier><identifier>EISSN: 1559-1182</identifier><identifier>DOI: 10.1007/s12035-013-8629-x</identifier><identifier>PMID: 24442481</identifier><language>eng</language><publisher>Boston: Springer US</publisher><subject>Animals ; Autophagy ; Biomedical and Life Sciences ; Biomedicine ; Brain - drug effects ; Brain - pathology ; Cell Biology ; Humans ; Multiple Sclerosis - drug therapy ; Multiple Sclerosis - pathology ; Nerve Degeneration - drug therapy ; Nerve Degeneration - pathology ; Neurobiology ; Neurodegeneration ; Neurology ; Neurons - drug effects ; Neurons - pathology ; Neuroprotective Agents - pharmacology ; Neurosciences ; Spinal Cord Injuries - drug therapy ; Spinal Cord Injuries - pathology</subject><ispartof>Molecular neurobiology, 2014-10, Vol.50 (2), p.368-389</ispartof><rights>Springer Science+Business Media New York 2014</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c475t-6b8fc1c74f04ab5b17d9d01f5641dbe6ba7d6c902f823812d19130b6d1fcd283</citedby><cites>FETCH-LOGICAL-c475t-6b8fc1c74f04ab5b17d9d01f5641dbe6ba7d6c902f823812d19130b6d1fcd283</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12035-013-8629-x$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12035-013-8629-x$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27923,27924,41487,42556,51318</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24442481$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Viscomi, Maria Teresa</creatorcontrib><creatorcontrib>Molinari, Marco</creatorcontrib><title>Remote Neurodegeneration: Multiple Actors for One Play</title><title>Molecular neurobiology</title><addtitle>Mol Neurobiol</addtitle><addtitle>Mol Neurobiol</addtitle><description>Remote neurodegeneration significantly influences the clinical outcome in many central nervous system (CNS) pathologies, such as stroke, multiple sclerosis, and traumatic brain and spinal cord injuries. Because these processes develop days or months after injury, they are accompanied by a therapeutic window of opportunity. The complexity and clinical significance of remote damage is prompting many groups to examine the factors of remote degeneration. This research is providing insights into key unanswered questions, opening new avenues for innovative neuroprotective therapies. In this review, we evaluate data from various remote degeneration models to describe the complexity of the systems that are involved and the importance of their interactions in reducing damage and promoting recovery after brain lesions. Specifically, we recapitulate the current data on remote neuronal degeneration, focusing on molecular and cellular events, as studied in stroke and brain and spinal cord injury models. Remote damage is a multifactorial phenomenon in which many components become active in specific time frames. Days, weeks, or months after injury onset, the interplay between key effectors differentially affects neuronal survival and functional outcomes. In particular, we discuss apoptosis, inflammation, oxidative damage, and autophagy—all of which mediate remote degeneration at specific times. We also review current findings on the pharmacological manipulation of remote degeneration mechanisms in reducing damage and sustaining outcomes. These novel treatments differ from those that have been proposed to limit primary lesion site damage, representing new perspectives on neuroprotection.</description><subject>Animals</subject><subject>Autophagy</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Brain - drug effects</subject><subject>Brain - pathology</subject><subject>Cell Biology</subject><subject>Humans</subject><subject>Multiple Sclerosis - drug therapy</subject><subject>Multiple Sclerosis - pathology</subject><subject>Nerve Degeneration - drug therapy</subject><subject>Nerve Degeneration - pathology</subject><subject>Neurobiology</subject><subject>Neurodegeneration</subject><subject>Neurology</subject><subject>Neurons - drug effects</subject><subject>Neurons - pathology</subject><subject>Neuroprotective Agents - pharmacology</subject><subject>Neurosciences</subject><subject>Spinal Cord Injuries - drug therapy</subject><subject>Spinal Cord Injuries - pathology</subject><issn>0893-7648</issn><issn>1559-1182</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1kN9LwzAQx4Mobk7_AF-k4Isv1VySpolvY_gLphPZe2ibZHS0zUxa2P57OzpFBOHgHu5z3zs-CF0CvgWM07sABNMkxkBjwYmMt0doDEkiYwBBjtEYC0njlDMxQmchrDEmBHB6ikaEMUaYgDHiH6Z2rYneTOedNivTGJ-1pWvuo9euastNZaJp0TofIut8tGhM9F5lu3N0YrMqmItDn6Dl48Ny9hzPF08vs-k8LliatDHPhS2gSJnFLMuTHFItNQabcAY6NzzPUs0LiYkVhAogGiRQnHMNttBE0Am6GWI33n12JrSqLkNhqiprjOuCAg59EUl5j17_Qdeu803_nIKE85RJSmVPwUAV3oXgjVUbX9aZ3ynAau9UDU5V71Ttnaptv3N1SO7y2uifjW-JPUAGIPSjZmX8r9P_pn4BYfuAWQ</recordid><startdate>20141001</startdate><enddate>20141001</enddate><creator>Viscomi, Maria Teresa</creator><creator>Molinari, Marco</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QR</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88G</scope><scope>88I</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>M2P</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope></search><sort><creationdate>20141001</creationdate><title>Remote Neurodegeneration: Multiple Actors for One Play</title><author>Viscomi, Maria Teresa ; Molinari, Marco</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c475t-6b8fc1c74f04ab5b17d9d01f5641dbe6ba7d6c902f823812d19130b6d1fcd283</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Animals</topic><topic>Autophagy</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Brain - drug effects</topic><topic>Brain - pathology</topic><topic>Cell Biology</topic><topic>Humans</topic><topic>Multiple Sclerosis - drug therapy</topic><topic>Multiple Sclerosis - pathology</topic><topic>Nerve Degeneration - drug therapy</topic><topic>Nerve Degeneration - pathology</topic><topic>Neurobiology</topic><topic>Neurodegeneration</topic><topic>Neurology</topic><topic>Neurons - drug effects</topic><topic>Neurons - pathology</topic><topic>Neuroprotective Agents - pharmacology</topic><topic>Neurosciences</topic><topic>Spinal Cord Injuries - drug therapy</topic><topic>Spinal Cord Injuries - pathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Viscomi, Maria Teresa</creatorcontrib><creatorcontrib>Molinari, Marco</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Chemoreception Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><jtitle>Molecular neurobiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Viscomi, Maria Teresa</au><au>Molinari, Marco</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Remote Neurodegeneration: Multiple Actors for One Play</atitle><jtitle>Molecular neurobiology</jtitle><stitle>Mol Neurobiol</stitle><addtitle>Mol Neurobiol</addtitle><date>2014-10-01</date><risdate>2014</risdate><volume>50</volume><issue>2</issue><spage>368</spage><epage>389</epage><pages>368-389</pages><issn>0893-7648</issn><eissn>1559-1182</eissn><abstract>Remote neurodegeneration significantly influences the clinical outcome in many central nervous system (CNS) pathologies, such as stroke, multiple sclerosis, and traumatic brain and spinal cord injuries. Because these processes develop days or months after injury, they are accompanied by a therapeutic window of opportunity. The complexity and clinical significance of remote damage is prompting many groups to examine the factors of remote degeneration. This research is providing insights into key unanswered questions, opening new avenues for innovative neuroprotective therapies. In this review, we evaluate data from various remote degeneration models to describe the complexity of the systems that are involved and the importance of their interactions in reducing damage and promoting recovery after brain lesions. Specifically, we recapitulate the current data on remote neuronal degeneration, focusing on molecular and cellular events, as studied in stroke and brain and spinal cord injury models. Remote damage is a multifactorial phenomenon in which many components become active in specific time frames. Days, weeks, or months after injury onset, the interplay between key effectors differentially affects neuronal survival and functional outcomes. In particular, we discuss apoptosis, inflammation, oxidative damage, and autophagy—all of which mediate remote degeneration at specific times. We also review current findings on the pharmacological manipulation of remote degeneration mechanisms in reducing damage and sustaining outcomes. These novel treatments differ from those that have been proposed to limit primary lesion site damage, representing new perspectives on neuroprotection.</abstract><cop>Boston</cop><pub>Springer US</pub><pmid>24442481</pmid><doi>10.1007/s12035-013-8629-x</doi><tpages>22</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0893-7648 |
ispartof | Molecular neurobiology, 2014-10, Vol.50 (2), p.368-389 |
issn | 0893-7648 1559-1182 |
language | eng |
recordid | cdi_proquest_miscellaneous_1611612936 |
source | MEDLINE; SpringerLink Journals - AutoHoldings |
subjects | Animals Autophagy Biomedical and Life Sciences Biomedicine Brain - drug effects Brain - pathology Cell Biology Humans Multiple Sclerosis - drug therapy Multiple Sclerosis - pathology Nerve Degeneration - drug therapy Nerve Degeneration - pathology Neurobiology Neurodegeneration Neurology Neurons - drug effects Neurons - pathology Neuroprotective Agents - pharmacology Neurosciences Spinal Cord Injuries - drug therapy Spinal Cord Injuries - pathology |
title | Remote Neurodegeneration: Multiple Actors for One Play |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T13%3A55%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Remote%20Neurodegeneration:%20Multiple%20Actors%20for%20One%20Play&rft.jtitle=Molecular%20neurobiology&rft.au=Viscomi,%20Maria%20Teresa&rft.date=2014-10-01&rft.volume=50&rft.issue=2&rft.spage=368&rft.epage=389&rft.pages=368-389&rft.issn=0893-7648&rft.eissn=1559-1182&rft_id=info:doi/10.1007/s12035-013-8629-x&rft_dat=%3Cproquest_cross%3E3448959071%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1566749339&rft_id=info:pmid/24442481&rfr_iscdi=true |